Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03844737
Other study ID # VF-OS-003/2018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 8, 2018
Est. completion date December 6, 2018

Study information

Verified date February 2019
Source VISUfarma SpA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

VisuXL® is a medical device that is effective in various ocular surface disorders (ocular dryness, changes in the continuity of the corneal and conjunctival surface, environmental stress, exposure to UV and ionizing radiation, prolonged use of videoterminals, etc.). Therefore, the aim of this study is to demonstrate that the clinical benefits and quality of life of the swimmers, exposed for a long time to water added with chlorine, are strongly linked to the unique composition of the long-term VisuXL® medical device.


Description:

This is a post-market, monocentric, open-label, randomized study of superiority, with the untreated eye considered as a comparator for the eye treated with VisuXL®, to demonstrate the effectiveness of VisuXL® in professional water-polo athletes exposed to pool water after VisuXL® ocular instillations for 2 months. Considered the category of subjects to study, the study is to be considered a fact-finding pilot study in a particular category of subjects.

The study population will be enrolled only after having signed the informed consent; in each enrolled subject, only one eye will be treated with VisuXL®, while the other no, as will be considered the comparator, so the two randomized groups will be divided by treated eyes:

- Untreated control eye

- Eye treated with VisuXL®

Each enrolled subject will be instructed to instill, TID, 1-2 drops of VisuXL® always in the same eye during the entire study, according to the present modality:

- Morning

- Before training (at least one hour before entering the pool)

- After training (maximum one hour after the end of the activity) Subjects will continue to instil 1-2 drops of VisuXL®, TID, always in the same eye, even in days without training (including weekends).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 6, 2018
Est. primary completion date December 6, 2018
Accepts healthy volunteers No
Gender Male
Age group 14 Years to 33 Years
Eligibility Inclusion Criteria:

1. Male subjects aged 14 to 33 years

2. Schirmer test I> 10 mm at 5 '

3. Willingness to participate in the study and possibility to sign the ICF; for athletes aged <18 years: parents' agreement for the participation of the child in the study

4. Discomfort of the ocular surface

Exclusion Criteria:

1. Pathologies of the anterior segment

2. Diagnosis of autoimmune diseases (eg SEL, Sjogren)

3. Diagnosis of metabolic diseases (eg diabetes, thyroid malfunction/disorder)

4. Entropion

5. Trichiasis

6. Deficiency of androgens sex hormones

7. Taking medications that can interfere with the secretion of the lacrimal gland

8. Connective tissue disease

9. Prior eye surgery

10. Hypersensitivity to the active ingredients contained in VisuXL®

11. Use of artificial tears in the 15 days before the start of the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
VisuXL®
Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.

Locations

Country Name City State
Italy UO Oculistica, Fondazione Policlinico Universitario A. Gemelli Roma

Sponsors (1)

Lead Sponsor Collaborator
VISUfarma SpA

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary break-up time (BUT) change over time in tear film break-up time (BUT) measured at week 1, 2, 4 and 8 versus baseline
Secondary coloration of the ocular surface Analysis to evaluate the differences over time between the two groups on coloration of the ocular surface (corneal and conjunctival) with fluorescein measured at week 1, 2, 4 and 8 versus baseline
Secondary Schirmer I test at 5 min (ST) (without anesthesia) Analysis to evaluate the differences over time between the two groups on Schirmer I test at 5 min (ST) (without anesthesia) measured at week 1, 2, 4 and 8 versus baseline
Secondary Number of beating of eyelashes per minute Analysis to evaluate the differences over time between the two groups on number of beating of eyelashes per minute measured at week 1, 2, 4 and 8 versus baseline
Secondary Tear osmolarity test Analysis to evaluate the differences over time between the two groups on tear osmolarity test measured at week 1, 2, 4 and 8 versus baseline
Secondary Evaluation of visual acuity Analysis to evaluate the differences over time between the two groups on evaluation of visual acuity measured at week 1, 2, 4 and 8 versus baseline
Secondary Questionnaire scores (OSDI) Analysis to evaluate the differences over time between the two groups on questionnaire scores (OSDI). The overall Ocular Surface Disease score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease. measured at week 1, 2, 4 and 8 versus baseline
Secondary Subject satisfaction (10 points on the VAS scale) Analysis to evaluate the differences over time between the two groups on subject satisfaction.
(VAS: scale where patient has to specify level of satisfaction by indicating a position along a continuous line between two end-points (0 - 10). 0 indicates no satisfaction while 10 represents the highest level).
measured at week 1, 2, 4 and 8
See also
  Status Clinical Trial Phase
Completed NCT01024751 - A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution N/A
Completed NCT03414645 - Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease Phase 1/Phase 2
Completed NCT03031327 - A 2 Weeks Study to Evaluate Tolerability, Safety, Permanence on the Ocular Surface and Efficacy of Two Concentrations of Lubricin Eye Drops Versus Sodium Hyaluronate 0.18% Eye Drops in Patients With Ocular Discomfort Following Refractive Surgery N/A
Withdrawn NCT03408015 - Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease Phase 4
Completed NCT03035864 - A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery Phase 2
Completed NCT04286945 - Lateral Rectus Muscle Tendon Elongation N/A
Completed NCT03302273 - Corneal Epithelial Stem Cells and Dry Eye Disease N/A